OncoACP3 is a small molecule radiotracer with ultra high-affinity for Acid Phosphatase 3 (ACP3).
ACP3 is a phosphatase that is abundantly expressed in prostate cancer but undetectable in normal organs, with exception of the healthy prostate. A side-by-side comparison between ACP3 and PSMA (currently considered the most validated marker of prostate cancer) has shown that ACP3 is more abundantly expressed in prostate cancer than PSMA, but cleaner in normal organs.
OncoACP3 displays best-in-class performance both in vitro and in vivo with the highest reported affinity to the ACP3 antigen. In preclinical models of cancer, the product has shown a rapid and selective accumulation in the tumor mass with an extraordinarily low uptake in normal organs (including kidneys and salivary glands).
OncoACP3 conjugated to ¹⁸F or ⁶⁸Ga is being developed for the non-invasive detection and staging of metastatic prostate cancer and is partnered with, a Bristol Myers Squibb Company.
